Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

TNFi Treatment Shows Hint of Slowing Axial Spondyloarthritis Radiographic Progression

Key clinical point: Tumor necrosis factor inhibitors (TNFi) may slow radiographic progression in the spine of patients with ankylosing spondylitis after at least 4 years of use.

Major finding: A analysis of six studies of TNFi with low risk of bias showed a significant effect of slowing radiographic progression at 4 years or more (modified Stoke Ankylosing Spondylitis Spine Score difference, –2.17).

Study details: A systematic review and meta-analysis of 24 studies to investigate effect of therapies on radiographic progression in axial spondyloarthritis, including 18 with TNFi, 8 with NSAIDs, and 1 with secukinumab (3 studies contained data for both NSAIDs and TNFi).

Disclosures: The work was funded by various grants from the National Institutes of Health. The authors reported no relevant disclosures.


Karmacharya P et al. Arthritis Rheumatol. 2020 Jan 20. doi: 10.1002/art.41206.